RecruitingPhase 4NCT05854615
Efficacy and Safety of Stempeucel® in Patients With Critical Limb Ischemia (CLI) Due to Buerger's Disease
Studying Buerger disease
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Cell Biopeutics Resources Sdn Bhd
- Principal Investigator
- Hanafiah Harunarashid, MSNational University of Malaysia
- Intervention
- Adult human bone marrow derived, cultured, pooled, allogeneic mesenchymal stromal cells(biological)
- Enrollment
- 3 enrolled
- Eligibility
- 18-65 years · All sexes
- Timeline
- 2024 – 2027
Study locations (1)
- Hospital Canselor Tunku Mukhriz, Kuala Lumpur, Malaysia
Collaborators
Stempeutics Research Pvt Ltd · National University of Malaysia
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT05854615 on ClinicalTrials.govOther trials for Buerger disease
Additional recruiting or active studies for the same condition.